Strategy
Generics in Switzerland
The portrait
In the market reached million Francs US million seven per cent growth in value over but market penetration still lags considerably behind the OECD average The reason the generics market is not yet fully developed in Switzerland is in large part due to a lack of incentives for doctors and pharmacists when it comes to prescription The Swiss generi...
Plotting Efficient Paths for Clinical Development
Clinical development is a complex puzzle with regulatory requirements epidemiology technology and specific clinical expertise all involved in how efficiently a product is developed and ultimately brought to market Many elements of this puzzle are closely related to geography and vary from one region to another As a result thoughtfully considering t...
Trends in Pharma Export Industry in India
While talking about the beginning of Indian pharmaceutical industry it begun in the late s and early s out of the need to meet local shortages and bring down the cost At that time most medicines were imported into India and market was dominated by MNCs Once domestic market was conquered by local companies there was a need to spread their wings in i...
Four Switches of Success
Life science firms exist to meet the needs of patients whilst simultaneously creating value for their shareholders or owners That much is obvious It is also apparent that firms vary greatly in their ability to do these two things the different longevities of companies tell us that What is much less clear is why firms differ so much in their ability...
The Future of Pharma Regulations
The Pharma industry at large is faced with challenges due to fast changing global regulations and many countries moving towards adopting a tighter control over drugs The patent cliff has pushed the industry to maximise their revenue from the existing portfolio in the past few years and thus resulted in expanding their market in emerging markets Thi...
Rigour or Rigmarole
Life sciences companies vary enormously in their size structure and processes but almost every firm shares the annual ritual of the strategic plan Whatever the business the intended outcome of this nearuniversal process is an agreed view on how the firm intends to win in the market place As such it ought to be seen as the most important and fundame...
Analytical Characterisations of Bio-Similar Products and Peptide-based Drugs
Biopharmaceuticals such as monoclonal antibodies and recombinant proteins have emerged as important lifethreatening therapeutics for the treatment of diseases including cancer Recently products are approved for various human diseases in the United States of America and the European Union Moreover biopharmaceuticals are currently in various stages...
Decision-making in Vaccines
How the fusion of price with access risks a tragedy of the commons
In four global vaccine producersSanofi Pasteur Merck Pfizer and GSKinvested significantly over US m each in global vaccines RD each year This has shrunk from global RD vaccine producers in and in Today there are only two producers for each of the northern hemispheres principle infant adolescent and adult vaccines In the past these RD based pro...
State of Pharmacovigilance
Proposals for streamlining the system
In recent years pharmacovigilance has been recognised as being one of the most important sciences in the health sector and this has led to develop new regulations and guidelines not only in Europe but also in the developing countries around the world The only goal of pharmacovigilance is protecting safety and this of course is also the aim of new r...
Growing the Regenerative Medicine Industry in Asia-Pacific with Help from Regulatory Science
Despite the scientific advances and progress in medicine there are only a few effective ways to treat the root causes of many injuries and diseases especially agerelated diseases Regenerative Medicine RM has the ability to repair and regenerate tissues and organs damaged by injuries diseases or the natural progression of age These therapies have th...
